Cannara Biotech Inc. LOVE.TO
TSX
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 22.78M | 19.75M | 21.55M | 20.54M | 19.39M |
| Total Other Revenue | 389.90K | 24.00K | 23.90K | 248.10K | 46.10K |
| Total Revenue | 23.17M | 19.78M | 21.57M | 20.79M | 19.44M |
| Cost of Revenue | 12.23M | 11.30M | 13.54M | 11.76M | 10.28M |
| Gross Profit | 10.94M | 8.48M | 8.03M | 9.03M | 9.16M |
| SG&A Expenses | 5.16M | 5.53M | 5.70M | 4.62M | 4.07M |
| Depreciation & Amortization | 173.50K | 184.10K | 191.10K | 567.00K | 158.70K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.81M | 17.30M | 19.63M | 17.08M | 14.63M |
| Operating Income | 5.36M | 2.48M | 1.94M | 3.71M | 4.81M |
| Income Before Tax | 5.00M | 2.05M | 1.46M | 3.31M | 4.12M |
| Income Tax Expenses | 1.48M | 842.10K | 717.30K | 894.80K | 1.17M |
| Earnings from Continuing Operations | 3.53M | 1.21M | 744.60K | 2.42M | 2.95M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.53M | 1.21M | 744.60K | 2.42M | 2.95M |
| EBIT | 5.36M | 2.48M | 1.94M | 3.71M | 4.81M |
| EBITDA | 6.50M | 3.38M | 3.02M | 5.29M | 5.66M |
| EPS Basic | 0.04 | 0.01 | 0.01 | 0.03 | 0.03 |
| Normalized Basic EPS | 0.03 | 0.01 | 0.01 | 0.02 | 0.03 |
| EPS Diluted | 0.04 | 0.01 | 0.01 | 0.02 | 0.03 |
| Normalized Diluted EPS | 0.03 | 0.01 | 0.01 | 0.02 | 0.03 |
| Average Basic Shares Outstanding | 98.78M | 96.36M | 93.72M | 91.44M | 91.43M |
| Average Diluted Shares Outstanding | 100.52M | 98.42M | 96.18M | 93.38M | 92.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |